Slide 1: ChromaDex Earnings Conference Call Third Quarter 2023
ChromaDex Earnings Conference Call Third Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | November 8, 2023
Slide 2: Safe Harbor Statement
This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-
Slide 3: Q3 2023 & Recent Highlights
Q3 2023 & Recent Highlights • Total company and Tru Niagen® net sales up 14% and 19% YoY, respectively. • Total sales and marketing expense was up $0.2 million while decreasing as a percentage of net sales YoY (31.0% vs 34.4%). • Delivered strong gross margins of 61.4%, up 160 basis points YoY, comp
Slide 4: Management Team
Management Team Rob Fried Brianna Gerber Heather Van Blarcom Chief Executive Officer Chief Financial Officer SVP, Legal & Corporate Secretary E-commerce & Over 20 years of diverse entertainment industry experience in investment Over two decades of executive management and finance industry experience
Slide 5: Financial Highlights
Financial Highlights 5 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 6: Q3 2023 Net Sales Mix
Q3 2023 Net Sales Mix Q3 2023 Q3 2022 E-Commerce E-Commerce Watson's & Other B2B 66% Watson's & Other B2B 65% 24% 19% $19.5 MM $17.1 MM Niagen® Ingredient 11% Niagen® Ingredient 7% Analytical Reference Analytical Reference Standards & Services Standards & Services 4% 4% • Tru Niagen® net sales incre
Slide 7: Q3 2023 Net Sales
Q3 2023 Net Sales Q3 2023 Net Sales Growth Rates ($ in millions) YoY % (vs Q3 2022) E-Commerce 12.7 +13% $17.4 Watson's & Other B2B 4.7 +43% Niagen® Ingredient 1.4 (21)% Analytical Reference 0.7 (2)% Standards & Services (100)% Other Ingredients 0.0 Total +14% Tru Niagen® business was up 19% year-ov
Slide 8: Year-to-Date 2023 Net Sales
Year-to-Date 2023 Net Sales Growth Rates YTD 2023 Net Sales ($ in millions) YoY % (vs YTD 2022) E-Commerce 37.9 +11% $51.9 Watson's & Other B2B 14.0 +42% Niagen® Ingredient 7.8 +78% Analytical Reference (6)% 2.2 Standards & Services +34% Other Ingredients 0.4 Total +22% Niagen®-related business(1),
Slide 9: 2021 – 2023 YTD Net Sales Summary
2021 – 2023 YTD Net Sales Summary ($ in millions) 2021 2022 2023 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 E-Commerce 9.6 10.6 10.5 11.1 41.8 10.9 12.0 11.3 11.1 45.3 12.2 13.0 12.7 Watsons 1.6 2.9 2.6 2.2 9.3 2.6 1.5 2.6 3.3 10.0 3.7 3.0 3.1 Other B2B 1.3 1.8 1.6 0.8 5.6 1.4 1.0 0.7 1.7 4.
Slide 10: Q3 2023 vs Q3 2022 Key P&L Metrics
Q3 2023 vs Q3 2022 Key P&L Metrics (in thousands) Q3 2023 Q3 2022 Notes Tru Niagen® business up 19% driven by E-Commerce growth (up +13%) and higher sales to distributor partners, including Watson’s, partially Net Sales $19,495 $17,063 offset by lower Niagen® ingredient sales primarily due to the ti
Slide 11: Adjusted EBITDA Summary
Adjusted EBITDA Summary ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three months ended Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Net loss, as reported $ (7,381) $ (5,566) $ (8,856) $ (5,325) $ (7,74
Slide 12: Q3 2023 Operating Loss vs Q3 2022
Q3 2023 Operating Loss vs Q3 2022 +$2.3 MM -$0.3 MM (in millions) — 0.1 0.2 (1.0) 0.2 (0.1) 0.3 (0.2) (1.1) 1.5 (2.0) (3.0) (3.1) Q3 2022 Volume Gross Margin Legal Other G+A Severance and Equity Comp Sales & Q3 2023 Operating Loss Improvement Restructuring (G+A) Marketing Operating Loss 12
Slide 13: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 12/31/20 12/31/21 3/31/22 6/30/22 9/30/22 12/31/22 3/31/23 6/30/23 9/30/23 Key Drivers (YoY for 2023 YTD) Cash $16,697 $28,219 $20,993 $17,072 $13,262 $20,441 $23,141 $26,406 $26,773 Driven by cash inflows from operations Driven by higher net sales a
Slide 14: Quarterly Cash Flow Highlights
Quarterly Cash Flow Highlights (in thousands) FY 2020 FY 2021 3/31/22 6/30/22 9/30/22 12/31/2022 FY 2022 3/31/23 6/30/23 9/30/23 Net Loss $ (19,925) $(27,128) $(7,740) $(6,397) $(985) (4) $(1,418) $(16,540) (4) $(1,902) $(2,191) $(959) Working Capital 383 (1) (4,915) (1,923) 923 (4,461) (4) (466) (5
Slide 15: 2023 Financial Outlook
2023 Financial Outlook (in thousands) 2021 Actual 2022 Actual 2023 Full Year Outlook Key Drivers • Includes steady growth from e-commerce Between 14% - 16% growth business, recurring revenues from established Net Sales $67,449 $72,050 (previously at least 15% growth, with partnerships, upside realiz
Slide 16: The Science
The Science 16 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 17: Science Continues to Expand
Science Continues to Expand • Four new human trials on nicotinamide riboside have registered since prior update.¹ • Antonio J. Conde Moreno & University of Valencia (June 2023) • To evaluate a skin cream's radioprotective and radiomitigation effect when used as a preventative treatment of acute radi
Slide 18: Recent Peer-Reviewed Clinical Publications
Recent Peer-Reviewed Clinical Publications • Movement Disorders – Presterud et al., 2023 – “Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia” – October 2023 • The study examined the safety and efficacy of long-term NR supplementation on neuromotor
Slide 19: Scientific Advisory Board
Scientific Advisory Board NOBEL PRIZE WINNERS | CHEMISTRY Charles Brenner, Ph.D. Roger Kornberg, Ph.D. Rudolph Tanzi, Ph.D. Alfred E Mann Family Chairman Kennedy Professor of Foundation Chair, Professor of Structural Neurology Department of Diabetes & Biology Harvard University Cancer Metabolism Sta
Slide 20: Basic Physiological Functions are NAD+ Dependent
Basic Physiological Functions are NAD+ Dependent INTRINSIC CAPACITY DOMAIN Based on World Health Organization’s definition VITALITY LOCOMOTION COGNITION SENSORY PSYCHOLOGICAL Energy metabolism Muscle strength Memory Mood Vision Hormonal function Balance Intelligence Hearing Emotional vitality Cardio
Slide 21: Contact Info
Contact Info: T: +1(949) 356-1620 InvestorRelations@ChromaDex.com www.chromadex.com Where to buy TRU NIAGEN® TruNiagen.com Amazon.com The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redis